These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16173723)

  • 21. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.
    Wu X; Liu Z; Ding X; Yu D; Wei H; Qin B; Zhu Y; Chong H; Cui S; He Y
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29321334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.
    Vaillant A; Juteau JM; Lu H; Liu S; Lackman-Smith C; Ptak R; Jiang S
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1393-401. PubMed ID: 16569857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
    J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
    An T; Ouyang W; Pan W; Guo D; Li J; Li L; Chen G; Yang J; Wu S; Tien P
    Antiviral Res; 2012 Jun; 94(3):276-87. PubMed ID: 22426469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A homogeneous time-resolved fluorescence assay to identify inhibitors of HIV-1 fusion.
    Smeulders L; Bunkens L; Vereycken I; Van Acker K; Holemans P; Gustin E; Van Loock M; Dams G
    Methods Mol Biol; 2013; 1030():11-7. PubMed ID: 23821256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
    Melikyan GB; Egelhofer M; von Laer D
    J Virol; 2006 Apr; 80(7):3249-58. PubMed ID: 16537592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
    Li W; Lu L; Li W; Jiang S
    Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-20 and T-1249 HIV fusion inhibitors' structure and conformation in solution: a molecular dynamics study.
    Martins Do Canto AM; Palace Carvalho AJ; Prates Ramalho JP; Loura LM
    J Pept Sci; 2008 Apr; 14(4):442-7. PubMed ID: 18069719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
    Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
    Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
    J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
    Zhao L; Tong P; Chen YX; Hu ZW; Wang K; Zhang YN; Zhao DS; Cai LF; Liu KL; Zhao YF; Li YM
    Org Biomol Chem; 2012 Aug; 10(32):6512-20. PubMed ID: 22760295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1.
    Galatola R; Vasconcelos A; Pérez Y; Cruz A; Pujol M; Alsina MA; Gómara MJ; Haro I
    Eur J Med Chem; 2014 Oct; 86():589-604. PubMed ID: 25218908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The N-Terminal T-T Motif of a Third-Generation HIV-1 Fusion Inhibitor Is Not Required for Binding Affinity and Antiviral Activity.
    Chong H; Qiu Z; Su Y; He Y
    J Med Chem; 2015 Aug; 58(16):6378-88. PubMed ID: 26256053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the sticky fingers of HIV-1.
    Blumenthal R; Dimitrov DS
    Cell; 2007 Apr; 129(2):243-5. PubMed ID: 17448985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
    Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
    Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor.
    Ashkenazi A; Wexler-Cohen Y; Shai Y
    Biochim Biophys Acta; 2011 Oct; 1808(10):2352-8. PubMed ID: 21762676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multimerized CHR-derived peptides as HIV-1 fusion inhibitors.
    Nomura W; Hashimoto C; Suzuki T; Ohashi N; Fujino M; Murakami T; Yamamoto N; Tamamura H
    Bioorg Med Chem; 2013 Aug; 21(15):4452-8. PubMed ID: 23800723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oligopeptide inhibitors of HIV-induced syncytium formation.
    Owens RJ; Tanner CC; Mulligan MJ; Srinivas RV; Compans RW
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1289-96. PubMed ID: 2078410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.